ArticleNeuroradiology2026
Assessment of paediatric craniopharyngioma progression: a comparison of contrast-enhanced and non-contrast MRI.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeStandard assessment of treatment response in craniopharyngioma (CP) includes volumetric measurement of solid and cystic tumour components on contrast-enhanced MRI. This study compared the detection of tumour progression using MRI with and without contrast administration.
methodsProgressive disease (PD) was assessed based on the measurement of tumour volume change using MRI without contrast. Contrast-enhanced MRI served as the reference standard.
resultsIn most patients, non-contrast T1- and T2-weighted sequences were sufficient to assess PD. Non-contrast MRI showed a sensitivity of 89.9%, specificity of 91.4%, positive predictive value of 0.90 (unadjusted; model-derived: 0.99), and negative predictive value of 0.90 (unadjusted; model-derived: 0.99). No improvement in the detection of PD based on CP metastatic implants along the surgical/interventional pathway was seen after contrast in our cohort. There were limitations in the detection of subtle tumour progression on non-contrast MRIs. In cases of a volume increase above the 25% threshold, particularly in the > 25-40% range, false-negative results may occur. Tumour progression with small initial volumes (≤ 0.8 cm³) may also be overlooked.
conclusionsFor CPs without volume increase or no detectable or measurable tumour residue, contrast administration may be omitted. Non-contrast MRI demonstrated high diagnostic accuracy. However, performance decreased in cases with 25-40% volume increase (grey zone), where contrast-enhanced MRI is recommended, as well as for CPs with a small tumour volume (≤ 0.8 cm³). The entire skull must be evaluated to rule out CP metastatic implants; high diagnostic image quality is required.
Indexed as
Identifiers
42678532What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.